Demand Optical Preclinical Imaging Market Increasing in Most Part of World 2027

The global optical preclinical imaging market size is expected to reach USD 543.0 million by the end of 2027, expanding at a CAGR of 3.3%, according to a new report by Grand View Research, Inc. Increasing number of preclinical studies aimed to study and develop various effective therapeutics for different diseases is a major factor boosting the adoption of optical preclinical imaging systems.

For instance, in December 2018, Bugworks Research, a drug discovery startup based in India, received US$ 3 million grant from CARB-X, a Boston-based organization. The grant was offered to support the development of preclinical trail for novel molecules to fight antimicrobial resistance. Moreover, various researchers are engaged in finding novel ways to increase the reproducibility and robustness of preclinical cancer research with an aim to reduce the failure rate of oncology clinical trials. Optical imaging also allows cost-effective and high-throughput animal study as compared to small animal molecular imaging technologies, including PET and MRI systems.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/optical-preclinical-imaging-market

Further key findings from the study suggest:

• North America accounted for the largest share in 2019 owing to well-established research infrastructure, adoption of guidelines for preclinical research, product approvals, and higher number of drug development projects
• Based on product type, in the device segment, bioluminescence captured the largest optical preclinical imaging market share in 2019 owing to high sensitivity and broad dynamic range as compared to other techniques for imaging animals used in various studies
• The bioluminescence segment is expected to witness significant growth over the forecast period due to increasing adoption of bioluminescence technology to visualize and study disease processes in laboratory animals
• By end use, the pharma and biotech companies segment accounted for the largest optical preclinical imaging market share in 2019 owing to increasing number of candidates in drug development studies and increasing focus on research and development for drug development and innovation
• The research institutes segment is expected to witness the fastest growth during the forecast period owing to rising adoption of advanced optical imaging systems in the research institutes
• Leading players operating in the market for optical preclinical imaging include Bruker; Perkin Elmer, Inc.; MR Solutions; BioTek Instruments, Inc.; Milabs B.V.; Fujifilm Holdings Corporation; Magnetic Insight, Inc.; MBF Bioscience; and Mediso Ltd.

Grand View Research has segmented the global optical preclinical imaging market on the basis of product type, end use, and region:

Optical Preclinical Imaging Product Type Outlook (Revenue, USD Million, 2016 - 2027)

• Device
  • Fluorescence
  • Bioluminescence
• Consumables
  • Fluorescence
    • Green fluorescent proteins
    • Red fluorescent proteins
    • Infrared dyes
    • Others
  • Bioluminescence
    • Luciferins
    • Proluciferins
    • Coelenterazine
    • Others
  • Software

Optical Preclinical Imaging End-use Outlook (Revenue, USD Million, 2016 - 2027)

• Pharma and Biotech Companies
• Research Institutes
• Others

Optical Preclinical Imaging Regional Outlook (Revenue, USD Million, 2016 - 2027)

• North America 
  • US.
  • Canada
• Europe
  • UK.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
• Asia Pacific
  • Japan
  • China
  • India
  • Malaysia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Columbia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Qatar

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Biohazard Bag Market Expected to Deliver Dynamic Progression By 2027

The global biohazard bags market size is anticipated to reach USD 472.3 million by 2027, expanding at a CAGR of 5.7% over the forecast period, according to a new report by Grand View Research, Inc. Growing population base, increasing awareness regarding the critical role of waste disposal in controlling human infection, and the rising hospital/healthcare standards in developing countries have together contributed to the market growth.

Waste disposal in biohazard bags is a critical step in maintaining the healthcare safety standards of medical institutions. Medical waste disposal in biohazard bags ensures that infectious waste isn’t exposed to the public and are disinfected or sterilized in a proper manner. Increasing awareness regarding hospital safety standards and investments by hospitals in maintaining their cleanliness are leading to increased use of biohazard bags, thereby propelling the biohazard bag market growth over the forecast period.

Biohazard bags allow proper handling of medical waste as the material used to handle medical waste needs to be tough, economical, and capable of creating an unbreakable containment. HDPE (High Density Polyethylene), LDPE (Low Density PolyEthylene), cellophane, and polyproylene are some commonly used materials for manufacturing biohazard bags. The materials and designs are generally autoclave safe, allowing them to be sterilized before disposal.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/bio-hazards-bag-market

Further key findings from the study suggest:

• On the basis of material type, LDPE dominated the market in 2019 as they are most commonly used owing to their high strength, low material cost, flexibility, considerable durability, and transparency
• Based on application, the others segment accounted for the largest share in 2019 and is anticipated to witness significant growth over the forecast period owing to rising awareness among housekeeping staff about disposing infectious wastes in medical institutions
• Hospitals and diagnostic labs are expected to witness the fastest growth over the forecast period owing to growing patient population, public awareness about healthcare, and resulting increasing demand for routine diagnostic testing/routine check-ups
• Middle East & Africa is expected to witness the fastest growth over the forecast period, closely followed by Asia Pacific owing to increasing awareness regarding the need to properly dispose hazardous medical waste and constantly improving healthcare facilities in the region
• Key players in the biohazard bags market include Bel-Art SP Scienceware, Dynalon, Heathrow, Thermo Scientific, MiniGrip, TufPak, Cole-Parmer, and Fisher Scientific.

Grand View Research has segmented the global biohazard bag market on the basis of product material, application, end use, and region:

Biohazard Bags Product Material Type Outlook (Revenue, USD Million, 2016 - 2027)

• HDPE
• LDPE
• Cellophane
• Polypropylene

Biohazard Bags Application Outlook (Revenue, USD Million, 2016 - 2027)

• Highly infectious
• Other Infectious
• Sharps
• Chemical & Pharmaceutical
• General Healthcare Waste
• Others

Biohazard Bags End-Use Outlook (Revenue, USD Million, 2016 - 2027)

• Hospitals
• Clinics
• Diagnostic Laboratories
• Pharmaceutical/Research Laboratories
• Others

Biohazard Bags Regional Outlook (Revenue, USD Million, 2016 - 2027)

• North America
  • US.
  • Canada
• Europe
  • UK.
  • Germany
  • France
  • Italy
  • Spain
  • ROE
• Asia Pacific
  • Japan
  • China
  • South Korea
  • India
  • Australia
  • Thailand
  • Indonesia
  • ROAPAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Columbia
  • ROLATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Turkey
  • Egypt
  • ROMEA

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

End Stage Renal Disease Market Valuation to Reach USD 172.0 Billion by the end of 2027

End Stage Renal Disease Market Growth & Trends

The global end stage renal disease market size is anticipated to reach USD 172.0 billion by 2027, exhibiting a CAGR of 12.4% over the forecast period, according to a new report by Grand View Research, Inc. Increasing number of patients suffering from kidney failure or end stage renal disease and rising prevalence of hypertension and diabetes are driving the market for end stage renal disease.

Chronic kidney disease (CKD) is one of the major causes of increase in the kidney failure rates among patients. According to the Centers for Disease Control and Prevention (CDC), approximately 37 million people in U.S suffer from CKD, whereas globally more than 500 million people (12-18% of world population) are affected. Moreover, at present, the highest prevalence rate of CKD is in China, U.S., Taiwan, Japan, Germany, France, Belgium, Africa, and Rest of Asia. It is also estimated that the number of cases of end stage renal disease or CKD will increase among the elderly population, especially in developing countries, such as China, India, and countries in Africa.

Technological advancements in the treatment of renal failure is another factor expediting the overall market growth. For instance, wearable artificial kidney (WAK) is a portable dialysis device designed to enable patients to live healthier as it controls blood pressure, improves clearance of wastes from the blood, and allows end stage renal disease or CKD patient for a less strict diet, resulting in lower fluid weight gain with less stress on the heart. Thus, WAK has the potential to reduce mortality in dialysis patients, thereby improving an end stage renal disease patient’s quality of life. The WAK prototypes designed and patented by innovative firms have been approved for human clinical trials by the U.S. FDA in 2016 with great success.

Key players in the market for end stage renal disease include Nipro Corporation; Fresenius Medical Care AG & Co. KGaA; Baxter International, Inc.; Medtronic Plc; B. Braun Melsungen AG; BD; Asahi Kasei Medical Co., Ltd; Cantel Medical; Nikkiso Co., Ltd; and JMS Co. Ltd. For instance, in October 2019, Fresenius Medical Care has received breakthrough device designation by U.S. FDA for its new hemodialysis machine that aims to prevent blood clotting without the use of any medication.

Request a free sample copy or view report summary: End Stage Renal Disease Market Report

End Stage Renal Disease Market Report Highlights

• Based on treatment, the dialysis segment dominated the market for end stage renal disease in 2019 owing to its ease of use and emergency convenience
• Asia Pacific led the market in 2019 owing to the large population of patients with CKD/ESRD and higher incidence of hypertension and diabetes in the region
• Key players operating in the market include Nipro Corporation; Fresenius Medical Care AG & Co. KGaA; Baxter International, Inc.; Medtronic Plc; B. Braun Melsungen AG; BD; Asahi Kasei Medical Co., Ltd; Cantel Medical; Nikkiso Co., Ltd; and JMS Co. Ltd.

End Stage Renal Disease Market Segmentation

Grand View Research has segmented the global end stage renal disease market on the basis of treatment and region:

End Stage Renal Disease Treatment Outlook (Revenue, USD Million, 2016 - 2027)

• Transplantation
• Dialysis
  • Peritoneal Dialysis
  • Hemodialysis
  • Wearable Artificial Kidney

End Stage Renal Disease Regional Outlook (Revenue, USD Million, 2016 - 2027)

• North America
  • US.
  • Canada
• Europe
  • UK.
  • Germany
  • France
  • Italy
  • Spain
• Asia Pacific (APAC)
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Latin America (LATAM)
  • Mexico
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Intragastric Balloon Market to Expand at a CAGR of 12.1% Through 2027

The global intragastric balloon market size is expected to reach USD 90.5 million by 2027, expanding at a CAGR of 12.1% over the forecast period, according to a new report by Grand View Research, Inc. Rise in obesity and increasing demand for minimally invasive procedures are the key factors driving the market.

Intragastric balloons are one of the most widely adopted endoscopic bariatric therapy devices in the clinical settings. This can be attributed to complications associated with surgical weight loss treatments and the low eligibility criteria for surgical options, thus leading to a rise in demand for effective minimally invasive weight-loss treatment options.

Safety concerns associated with intragastric balloons are anticipated to make the regulatory framework more stringent for pre-market and post-market scrutiny process of these devices. For instance, in 2019, Apollo Endosurgery Inc. revised the labeling of its Orbera intragastric balloon system to include contradiction clarifications, precautions related to anticholinergic and psychotropic medications, and updated U.S. adverse event tables after it received FDA safety letter.

Nonetheless, extensive research activities related to the development of innovative and novel systems and up-gradation of existing intragastric balloons to overcome the shortcomings of the traditional systems are anticipated to facilitate the intragastric balloon market growth.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/intragastric-balloon-market

Further key findings from the study suggest:

• According to the American Society for Metabolic and Bariatric Surgery (ASMBS) data, nearly 5,000 intragastric balloon implantations have been conducted since the U.S. FDA approval
• The single balloon type segment held the largest share in the market in 2019. The triple type is expected to witness significant growth over the forecast period
• By filling material, gas-filled systems are anticipated to witness lucrative growth over the forecast period
• Based on end use, hospitals held a significant share in 2019. Ambulatory surgical centers are expected to witness considerable growth from 2020 - 2027
• On the basis of administration, endoscopy held the dominant market share in 2019. Pill form is expected to witness lucrative growth over the forecast period
• North America dominated the intragastric balloon market in 2019 due to the presence of a large obese population and high adoption of bariatric procedures. Asia Pacific is expected to witness remunerative growth over the forecast period
• Some of the key companies operating in the market are Apollo Endosurgery, Inc.; Obalon Therapeutics, Inc; ReShape Medical, Inc; Allurion Technologies, Inc.; Spatz3; Helioscopie; Endalis; MEDSIL; and Lexel Medical
• As of January 2019, Apollo Endosurgery, Inc. has discontinued the sales and distribution of its ReShape Balloon.

Grand View Research has segmented the global intragastric balloon market on the basis of administration, balloon type, filling material, end use, and region:

Intragastric Balloon Administration Outlook (Revenue, USD Million, 2016 - 2027)

• Pill Form
• Endoscopy

Intragastric Balloon Type Outlook (Revenue, USD Million, 2016 - 2027)

• Single
• Dual
• Triple

Intragastric Balloon Filling Material Outlook (Revenue, USD Million, 2016 - 2027)

• Saline Filled
• Gas Filled

Intragastric Balloon End-use Outlook (Revenue, USD Million, 2016 - 2027)

• Hospitals
• Clinics
• Ambulatory Surgical Centers

Intragastric Balloon Regional Outlook (Revenue, USD Million, 2016 - 2027)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
  • France
  • Italy
  • Spain
  • The Netherlands
  • Belgium
  • Switzerland
  • Turkey
  • Poland
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Colombia
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Egypt

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Telemedicine Market is Expected to Grow at a CAGR of 15.1% over the Forecast Period

The global telemedicine market size is expected to reach USD 155.1 billion by 2027, expanding at a CAGR of 15.1% over the forecast period, according to a new report by Grand View research, Inc. Increasing incidences of chronic conditions and rising demand for self-care medicines are the key factors driving the market. Furthermore, increasing use of internet applications, ease of telemedicine, and rising demand for centralization of healthcare are expected to help save cost, which is one of the critical factors for the telemedicine market growth.

The healthcare industry is enormously huge and its centralization is expected to help in harmonizing the entire process as well as providing economic assistances. The unprecedented outbreak of COVID-19 across the globe has resulted into increased demand for telemedicine solutions, due to lockdown implemented by several countries as a preventive measure to curb the pandemic.

Moreover, owing to their capability to monitor various chronic conditions such as diabetes, cardiovascular conditions, and cancer, telemedicine solutions are expected to experience substantial development in the coming years. Growing prevalence of cardiac conditions, increase in geriatric population, and the constant demand for self-governing by patients are the high impact rendering drivers of this industry.

Telemedicine is helping in reducing the emergency room visits and hospitalization rate, thereby augmenting the market growth. Moreover, improving therapeutic infrastructure, growing post-acute care supervision, and rising demand in the emerging economies are expected to further propel the demand. 

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/telemedicine-industry

Further key findings from the study suggest:

• The products sub-segment registered largest revenue share in 2019 due to increasing adoption of remote monitoring devices
• Telemedicine found wide applications in dermatology, psychiatry, intensive care units, emergency care, ophthalmology, and radiology, out of which, teleradiology accounted for the majority of revenue in 2019
• Web/mobile based delivery model is expected to witness significant growth in coming years due to high adoption of smartphones and penetration of internet
• The tele-homecare segment is anticipated to expand at a lucrative CAGR in coming years due to increasing awareness regarding remote healthcare benefits among patients and introduction of advanced technologies to remotely monitor patient’s health
• The provider end-use segment held the dominant share of overall market in 2019. Government initiated healthcare programs across the world are anticipated to propel the adoption of telemedicine solutions by patients and providers in coming years
• North America dominated the global telemedicine market in 2019 and is still dominating as there is high adoption of telehealth solution due to COVID-19 pandemic. Availability of advanced healthcare facilities along with funds for the emergency care delivery in order to stop the spread of the disease is contributing toward regional growth
• Asia Pacific is predicted to witness lucrative growth over the forecast period owing to developing economies such as China and India facing challenges to provide access to patients due to corona outbreak. Economic reforms, booming IT industry, and low functioning costs are the key factors attracting market players in this region
• Some of the key players in the market are IBM; Intel Corporation; Teladoc; Doctor on Demand; iCliniq; Philips Healthcare; McKesson Corporation; AMD Telemedicine; and Cardio Net Inc.

Grand View Research has segmented the global telemedicine market by component, technology, application, delivery model, type, end use, and region:

Telemedicine Component Outlook (Revenue, USD Million, 2016 - 2027)

• Product
  • Hardware
  • Software
  • Others
• Services
  • Tele-consulting
  • Tele-monitoring
  • Tele-education

Telemedicine Technology Outlook (Revenue, USD Million, 2016 - 2027)

• Store and Forward
• Real Time
• Others

Telemedicine Application Outlook (Revenue, USD Million, 2016 - 2027)

• Teleradiology
• Telepsychiatry
• Telepathology
• Teledermatology
• Telecardiology
• Others

Telemedicine Delivery Model Outlook (Revenue, USD Million, 2016 - 2027)

• Web/Mobile
  • Telephonic
  • Visualized
• Call Centers

Telemedicine Type Outlook (Revenue, USD Million, 2016 - 2027)

• Tele-hospital
• Tele-home

Telemedicine End Use Outlook (Revenue, USD Million, 2016 - 2027)

• Providers
• Payers
• Patients
• Others

Telemedicine Regional Outlook (Revenue, USD Million, 2016 - 2027)

• North America
  • US.
  • Canada
• Europe
  • UK.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Switzerland
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Singapore
  • Malaysia
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Artificial Intelligence In Healthcare Market to Surpass USD 31.3 Billion by 2025

Artificial Intelligence in Healthcare Market Growth & Trends

The global artificial intelligence in healthcare market size is expected to reach USD 31.3 billion by 2025, growing at a CAGR 41.5% over a forecast period, according to a new report by Grand View Research, Inc. The rising demand to reduce healthcare costs, increasing adoption of precision medicine, growing importance of big data in healthcare, and declining hardware costs are some factors propelling adoption of AI technology in healthcare industry. Moreover, rise in potential applications of AI-based tools in medical care and growth in venture capital investments are anticipated to aid growth over the forecast period.

Rise in the number of cross-industry collaborations is anticipated to fuel growth. For instance, in March 2018,Microsoft announced partnership with Apollo Hospitals, one of the prominent healthcare systems in India. The partnership was focused on developing and deploying new machine learning models for predicting the risk of developing cardiac diseases and aid doctors in treatment planning. Increase in venture capital funding is a key factor propelling growth of AI start-ups, which is further contributing to market growth.

The adoption of AI in healthcare is increasing, as healthcare providers are focused on enhancing patient care further. The adoption of this technology in healthcare has various benefits, both patients and healthcare providers. AI enables personalized care, based on body constitution and past medical history. Moreover, the shortage of physicians in some countries is anticipated to increase demand for AI in healthcare.

Request a free sample copy or view report summary: Artificial Intelligence in Healthcare Market Report

Artificial Intelligence in Healthcare Market Report Highlights

• In 2018, software solutions held the largest revenue share owing to the development of AI-based software solutions for the healthcare sector
• Clinical trials held the largest revenue share in 2018, and this can be attributed to the growing focus of pharmaceutical companies on incorporating AI in automation of clinical trial processes.
• North America held the largest revenue share, owing to high adoption of healthcare IT solutions in the region and availability of well-established healthcare infrastructure
• Asia Pacific is expected to exhibit the fastest CAGR over the forecast period, owing to growing AI-based start-ups, improving healthcare IT infrastructure, and increasing adoption of advanced technologies.
• Some key players are IBM Corporation; NVIDIA Corporation, Nuance Communications, Inc.; Microsoft; Intel Corporation; and DeepMind Technologies Limited

Artificial Intelligence in Healthcare Market Segmentation

Grand View Research has segmented the artificial intelligence in healthcare market on the basis of component, application, and region:

Artificial Intelligence in Healthcare Component Outlook (Revenue, USD Million, 2014 - 2025)

• Software Solutions
• Hardware
• Services

Artificial Intelligence in Healthcare Application Outlook (Revenue, USD Million, 2014 - 2025)

• Robot Assisted Surgery
• Virtual Assistants
• Administrative Workflow Assistants
• Connected Machines
• Diagnosis
• Clinical Trials
• Fraud Detection
• Cybersecurity
• Dosage Error Reduction

Artificial Intelligence in Healthcare Regional Outlook (Revenue, USD Million, 2014 - 2025)

• North America
  • US.
  • Canada
• Europe
  • UK,
  • Germany
  • Spain
  • Italy
  • Russia
  • France
• Asia Pacific
  • Australia
  • Japan
  • South Korea
  • India
  • China
  • Singapore
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Veterinary Pain Management Market to Reflect a Significant CAGR of 5.3% by 2026

The Report Veterinary Pain Management Market Size, Share & Trends Analysis Report By Product (NSAIDs, Anesthetics), By Indication, By Animal Type (Companion, Livestock), By End Use, And Segment Forecasts, 2019 - 2026

The global veterinary pain management market size is expected to reach USD 1.73 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 5.3% during the forecast period. Growing companion adoption and incidence of veterinary diseases is expected to boost the growth. Moreover, increasing income in the developing countries is another growth driver. For instance, according to the American Veterinary Medical Association (AVMA) in 2017, around 46% household had multiple types of pets in U.S.

North America held the dominant share of the veterinary pain management market in 2018, due to the favorable pet insurance policies and strategic initiatives adopted by various companies operating in the region. For instance, in August 2018, Zoetis Inc. acquired Abaxis in a probe to expand its veterinary products portfolio.

Increasing number of veterinary practitioners are anticipated to create growth opportunities in the market. High prevalence of chronic diseases such as cancer, diabetes, and osteoarthritis among others. These factors are projected to propel the market in the forthcoming years.

Furthermore, key players are implementing newer strategies such as product launch, merger and acquisitions, regional expansions etc. for increasing their foothold in the market. For instance, in March 2016, Dechra Pharmaceuticals acquired Putney in order to improve its animal product portfolio. In October 2018, Boehringer Ingelheim invested USD 80 million for R&D pertinent to veterinary vaccines in France. Moreover, increasing pet insurance coverage are further fueling the market growth.

Access Research Report of Veterinary Pain Management Market @ https://www.grandviewresearch.com/industry-analysis/veterinary-pain-management-market

Further key findings from the report suggest:

• NSAIDs accounted for the largest market share in terms of revenue in 2018, owing to the increasing incidence of chronic diseases
• Companion animal segment is expected to exhibit lucrative growth over the forecast period owing to rise in pet adoption and expenditure for better pet care
• Osteoarthritis (OA) segment is expected to hold the largest market share in terms of revenue due to increasing incidence of obesity which propels the risk for OA
• Post-operative pain segment is expected to exhibit lucrative growth over the forecast period due to the increasing number of surgeries for chronic disorders
• Asia Pacific is anticipated to witness lucrative growth due to rise in pet adoption and expendable income, especially in Japan and India
• Some of the key companies operating in the veterinary pain management market are Zoetis, CEVA, Boehringer Ingelheim GmbH, Bayer, Merck, and Elanco.

Grand View Research has segmented the global veterinary pain management market on the basis of product, indication, animal type, end use, and region:

Veterinary Pain Management Product Outlook (Revenue, USD Million, 2014 - 2026)

• NSAIDs
• Anesthetics
• Opioids
• Others

Veterinary Pain Management Indication Outlook (Revenue, USD Million, 2014 - 2026)

• Osteoarthritis
• Post-operative pain
• Others

Veterinary Pain Management Animal Type Outlook (Revenue, USD Million, 2014 – 2026

• Livestock animal
• Companion Animal

Veterinary Pain Management End Use Outlook (Revenue, USD Million, 2014 - 2026)

• Hospitals & Clinics
• Others

Veterinary Pain Management Regional Outlook (Revenue, USD Million, 2014 - 2026)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Medical Device Complaint Management Market Poised to Expand at a Robust Pace of USD 10.2 Billion Over 2026

Medical Device Complaint Management Market Growth & Trends

The global medical device complaint management market size is expected to reach USD 10.2 billion by 2026, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 7.6% during the forecast period. Increasing use of software to support the entire complaint management process is propelling the growth.

The transition from paper-based to digital system for tracking complaints is boosting growth of the market. Incidents are recorded and the data automatically drives the investigation and resolution workflow. Companies experience more complete documentation along with the reduction in the turnaround time. The complaints management solution provides advanced analytics and reporting tools for augmented management oversight. The software also streamlines the submissions with standard reporting for the EU, FDA, Japan, Health Canada, and Australia.

For instance, the U.S. FDA encourages consumers, patients, and healthcare professionals to give voluntary reports of important adverse events, and/or product issues to MedWatch, FDA’s Safety Information and Adverse Event Reporting Program or by means of the mobile app known as MedWatcher. The app radically simplifies and accelerates the process of reporting by providing users with a four-step form submitted electronically to the FDA.

Regulators are gradually concentrating on handling customer complaints, product safety, and device vigilance. This is not only true in developed countries, but also in emerging economies such as India. The Indian government introduced medical devices regulation program, Materiovigilance Programme of India (MvPI) with focus on safety data collection, synchronization of international laws, regulations, and standards encourages medical device organizations to evaluate their existing procedures of product development and post-marketing surveillance.

Request a free sample copy or view report summary: Medical Device Complaint Management Market Report

Medical Device Complaint Management Market Report Highlights

• Product surveillance and regulatory compliance emerged as the largest segment owing to greater emphasis put on product surveillance by regulatory agencies
• North America held the largest market share in 2017 owing to stern regulatory requirements and heavy monetary fines in this region. All the device manufacturers, importers, and distributors are required to comply with the complaint and record requirement
• Some of the key players operating in the medical device complaint management market include IQVIA, Wipro, Tata Consulting Services, SAS, Sparta Systems, Parexel International Corporation, Biovia, AssurX, MasterControl, and Freyr.

Medical Device Complaint Management Market Segmentation

Grand View Research has segmented the global medical device complaint management market based on service and region:

Medical Device Complaint Management Service Outlook (Revenue, USD Million, 2014 - 2026)

• Complaints Log / Intake
  • Receive Complaints
  • Classify the Issue
  • Record Issue
• Product Surveillance & Regulatory Compliance
  • Reportable/Non Reportable
  • Medical Device Vigilance/Medical Device Reporting
  • Field Action
• Returned/ Non-Returned Product Analysis
  • Complaint Investigation
  • Root Cause Analysis, Testing
  • Corrective/Preventive Action
• Resolve & Closure
  • Complaint Summary
  • Customer Letter Creation

Medical Device Complaint Management Regional Outlook (USD Million, 2014 - 2026)

• North America
  • US.
  • Canada
• Europe
  • UK.
  • Germany
• Asia Pacific
  • Japan
  • China
• Latin America
  • Brazil
  • Mexico
• Middle East & Africa
  • South Africa
  • Saudi Arabia

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Fractional Flow Reserve Market Increase at a CAGR of 10.4% from 2019 to 2026

Fractional Flow Reserve Market Growth & Trends

The global fractional flow reserve market size is expected to reach USD 1.20 billion by 2026, according to a new report by Grand View Research, Inc. expanding at a CAGR of 10.4% over the forecast period. widening base of cardiovascular diseases coupled with mounting cases of diabetes in developed as well as developing economies is escalating the growth of the market. Furthermore, launch of novel devices in fractional flow reserve (FFR) market such as guidewires and monitoring systems are also anticipated to aid market growth. For instance, in May 2019, Philips launched IntraSight interventional applications platform. This platform offers comprehensive unit of IVUS, FFR, IFR and co-registration modalities to speed up the routine procedures and simplify complex interventions.

In an independent study by SCAI, in 2019 it was observed that FFR possess the capability to decide the treatment plan for Acute Coronary Syndrome (ACS) which could be either PCI (Percutaneous Coronary Intervention) or CABG (Coronary Artery Bypass Grafting). This is anticipated to help the physicians and provide effective treatment plan to patients, thereby increasing adoption of the same in coming five years.

Moreover, consolidation activities, such as acquisition of St. Jude by Abbott in 2017 in order to increase its foothold in the cardiovascular devices market, is likely to keep the market highly competitive and thereby, augur well for the overall market.

Request a free sample copy or view report summary: Fractional Flow Reserve Market Report

Fractional Flow Reserve Market Report Highlights

• FFR monitoring systems accounted for significant share of over 40.0% in 2018 owing to the extensive usage in single and multiple vessel CAD.
• FFR guidewires is expected grow at a profitable growth rate over the forecast period due to increase in fractional flow reserve procedures conducted globally.
• North America held the significant share of FFR devices industry as of 2018, due to the increased investment in R&D by the medical device companies. For instance, a bill was approved by the U.S. congress in May 2018 via which an individual can try unproven medical aids comprising drugs, medications and devices in case of severe illness.
• Asia Pacific regional FFR industry is anticipated to witness major growth due to rising healthcare spending and rise in diabetes cases in countries such as China and India.
• Some of the key companies operating in the fractional flow reserve market are OPSENS Medical, Abbott Laboratories, Boston Scientific, and Bracco S.p.A. among others.
• The industry participants are engaged in extensive research activities to develop novel FFR devices for diagnosis of cardiac disorders.

Fractional Flow Reserve Market Segmentation

Grand View Research has segmented the global fractional flow reserve report on the basis of product, application, and region:

Fractional Flow Reserve Product Outlook (Revenue, USD Million; 2014 - 2026)

• FFR guidewires
• FFR monitoring systems

Fractional Flow Reserve Application Outlook (Revenue, USD Million; 2014 - 2026)

• Multi-vessel coronary artery disease
• Single-vessel coronary artery disease

Fractional Flow Reserve Regional Outlook (Revenue, USD Million; 2014 - 2026)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Mexico
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Turkey

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Clinical Oncology Next Generation Sequencing Market Expected to Deliver Dynamic Progression By 2025

The global clinical oncology next generation sequencing (NGS) market size is expected to reach USD 1.5 billion by 2025, according to a new report by Grand View Research, Inc., registering a CAGR of 13.2% over the forecast period. Rise in demand for personalized medicine, coupled with growth in next generation sequencing technology, is anticipated to accelerate the growth of NGS technology in clinical diagnostics.

Owing to the fact that next generation sequencing offers several advantages such as sensitivity, accuracy, and speed, this technology is anticipated to drive the oncology clinical diagnostics market. Furthermore, next generation sequencing aids in the assessment of multiple genes in a single assay, thereby eliminating the need to order several tests for determination of underlying mutation.

North America held the dominant share in the global the market for clinical oncology NGS in 2018 owing to increased focus of government bodies on cancer treatment, rise in healthcare expenditure, and presence of adequate infrastructure in the healthcare industry. Asia Pacific is expected to be the fastest-growing regional market throughout the forecast period majorly due to continuous reforms in the healthcare and pharmaceutical industries in the region. Presence of untapped markets in emerging economies in the region will also benefit regional growth. 

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/clinical-oncology-next-generation-sequencing-ngs-market

Further key findings from the report suggest:

• By technology, targeted sequencing and resequencing held the largest share in 2018 owing to frequent usage in cancer diagnostics. On the other hand, whole-genome sequencing (WGS) is expected to grow at a lucrative rate owing to wide-scale applications and rising demand for the technique
• Based on application, companion diagnostics is anticipated to witness the fastest growth as a consequence of presence of a substantial number of pharmaceutical and diagnostic developers collaborating to commercialize the products. These participants are focused on extensive R&D in companion diagnostics to obtaining regulatory approval for novel assays combined with pharmaceuticals
• On the basis of end use, the clinics segment will expand at a significant growth rate thanks to increase in feasibility for the use of next generation sequencing technology
• North America occupied the largest share owing to increased focus of government bodies on cancer treatment, rise in healthcare expenditure, and presence of adequate healthcare infrastructure
• Asia Pacific is expected to grow at the fastest rate due to continuous reforms in the healthcare and pharmaceutical sectors, accompanied by improvement in reimbursement policies
• Illumina, Inc.; Thermo Fisher Scientific; F. Hoffmann-La Roche Ltd; Agilent Technologies; Myriad Genetics; Beijing Genomics Institute (BGI); Perkin Elmer; Foundation Medicine; Pacific Bioscience; Oxford Nanopore Technologies Ltd; Paradigm Diagnostics; Caris Life Sciences; Partek, Inc.; Eurofins Scientific S.E; and Qiagen N.V. are some of the key participants operating in this market. These participants are engaged in new product development and strategic alliances for enhancing their competitive footprint in the market.

Grand View Research has segmented the global clinical oncology NGS market on the basis of technology, workflow, application, end use, and region:

Clinical Oncology NGS Technology Outlook (Revenue, USD Million, 2014 - 2025)

• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing & Resequencing

Clinical Oncology NGS Workflow Outlook (Revenue, USD Million, 2014 - 2025)

• NGS Pre-Sequencing
• NGS Sequencing
• NGS Data Analysis

Clinical Oncology NGS Application Outlook (Revenue, USD Million, 2014 - 2025)

• Screening
  • Sporadic Cancer
  • Inherited Cancer
• Companion Diagnostics
• Others

Clinical Oncology NGS End-use Outlook (Revenue, USD Million, 2014 - 2025)

• Hospitals
• Clinics
• Laboratories

Clinical Oncology NGS Regional Outlook (Revenue, USD Million, 2014 - 2025)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
• Asia Pacific
  • Japan
  • China
• Latin America
  • Brazil
• Middle East and Africa (MEA)
  • South Africa

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

U.S. Population Health Management Market is Anticipated to Generate Significant Revenues by 2027

U.S. Population Health Management Market Growth & Trends

The U.S. population health management market size is expected to reach USD 62.2 billion in 2027, registering a CAGR of 20.5% over the forecast period, according to a new report by Grand View Research, Inc. Increase in healthcare expenditure, need for value-based healthcare delivery, and effective disease management across different care settings are among key factors likely to drive the market during the forecast period.

Population health management stratifies population groups at risk and identifies high cost diseases and conditions, ultimately deriving the members that need to participate in disease management programs. Furthermore, insurance providers have initiated partnerships with healthcare providers through PHM integration for cost containment and value delivery. Due to the shift of healthcare providers and payers from volume to value-based care delivery, tools like PHM solutions are critical in addressing their needs. PHM solutions are an important part of Quality Payment Program (QPP), launched by the Centers for Medicare & Medicaid Services (CMS).

In U.S., poor healthcare management results in the loss of productivity and a significant portion of healthcare costs. Adoption of PHM software by employers helps in the management of their healthcare budget as they can keep a track of the employees’ health status. The U.S. PHM market is likely to witness rapid growth in the coming years due to growing demand for healthcare IT services and solutions that encourage healthcare delivery reliant on value, resulting in a transition from Fee-For-Service to a value-based payment model.

Request a free sample copy or view report summary: U.S. Population Health Management Market Report

U.S. Population Health Management Market Report Highlights

• In 2010, the U.S. government introduced the Patient Protection and Affordable Care Act, which ensures provision of high-quality care, while reducing cost. This has encouraged the establishment of various Accountable Care Organizations (ACOs)
• Increase in healthcare expenditure, need for value-based healthcare delivery, and effective disease management across different care settings is expected to propel the U.S. population health management market growth
• The services segment dominated the overall market in terms of revenue in 2019, while the software segment is likely to experience the fastest growth over the forecast period
• Healthcare providers held a majority of the market in 2019 as population health management gives providers the flexibility to manage complex clinical data and assist in generating real-time insights. These functionalities and advantages offered by PHM are responsible for its increased adoption by healthcare providers
• Some of the companies operating in this market are Cerner; Allscripts Healthcare, LLC; Conifer Health Solutions, LLC; eClinicalWorks; Enli Health Intelligence; McKesson Corporation, Optum, Inc.; Advisory Board; Koninklijke Philips N.V.; and athenahealth, Inc.
• In May 2018, Allscripts acquired HealthGrid Holding Company, enabling Allscripts to integrate HealthGrid’s capabilities into its FollowMyHealth platform.

U.S. Population Health Management Market Segmentation

Grand View Research has segmented the U.S. population health management market based on product and end use:

U.S. Population Health Management Product Outlook (Revenue, USD Million, 2016 - 2027)

• Software
• Services 

U.S. Population Health Management End-use Outlook (Revenue, USD Million, 2016 - 2027)

• Provider
• Payers
• Employer Groups

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Sternal Closure Systems Market to Grow at Moderate CAGR of 5.4% Through 2026

The Report Sternal Closure Systems Market Size, Share & Trends Analysis Report By Product (Closure Devices, Bone Cement), By Material (Stainless Steel, PEEK, Titanium), By Procedure, And Segment Forecasts, 2018 - 2025

The global sternal closure systems market size is expected to reach USD 2.96 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 5.4% during the forecast period. The market is driven by growing number of surgeries undertaken to treat complex cardiovascular problems. For instance, according to data published by American Heart Association (AHA), around 520,000 Coronary Artery Bypass Graft (CABG) surgeries were performed in the U.S. in 2014. The report further states that more than 800,000 CABG surgeries are performed worldwide every year.

Furthermore, the National Health Interview Survey conducted by CDC in 2016 concluded that 28.1 million people in the U.S. were diagnosed with heart related disorders, including valvular heart disease and cardiac arrest. Moreover, increasing research and development activities are paving way for advanced systems such as talon systems and double sternal wires. This, coupled with favorable reimbursement criteria, is bolstering market growth.

Mergers and acquisitions, new product development, and geographical expansion are key strategies adopted by players to stay ahead in the market. For instance, KLS Martin, started its sales operations in the U.K., the Netherlands, Italy, France, Australia, Russia, Dubai, Japan, Malaysia, and Brazil in last couple of years in order to increase its geographical presence. The company is also focusing on Asia Pacific due to presence of large patient pool in the region. In line with the strategy, in June 2016, the company started a manufacturing unit in Chennai, India.

Request a free sample copy or view report summary: Sternal Closure Systems Market Report  
                                                                                                             

Further key findings from the report suggest:

• Rising adoption of cardiothoracic surgeries, including Coronary Artery Bypass Graft (CABG), Aortic valve surgery, and Arrhythmia surgery, is projected to augment the market
• Growing population of geriatrics across the globe is expected to stoke the growth of the market
• The closure devices segment held the leading share in the global arena in 2017, owing to introduction of technologically advanced clips and wires globally and favorable reimbursement regulations offered in developed regions such as North America and Europe
• The PEEK segment is anticipated to post significant growth over the coming years due to several benefits offered by the material, including biocompatibility, chemical resistance, end-product purity, high temperature resistance, and thermoformable nature
• North America dominated the market in 2017. The growth of the region can be attributed to presence of a large number of players and high competitive rivalry in the market. Moreover, rising adoption of technologically advanced systems coupled with presence of skilled professionals are likely to provide a fillip to the regional market
• Asia Pacific is poised to register the highest CAGR during forecast period. Increasing per capita income, improving healthcare infrastructure, and rising patient pool are estimated to drive the market
• The market is currently consolidated, with few companies capturing major shares. However, increasing demand for innovative technologies and recent market dynamics are making way for new entrants.

Grand View Research has segmented the global sternal closure systems market on the basis of product type, material, procedure, and region:

Sternal Closure Systems Product Outlook (Revenue, USD Million, 2014 - 2025)

• Closure Devices
• Bone Cement

Sternal Closure Systems Material Outlook (Revenue, USD Million, 2014 - 2025)

• Titanium
• Polyether Ether Ketone (PEEK)
• Stainless Steel
• Others

Sternal Closure Systems Procedure Outlook (Revenue, USD Million, 2014 - 2025)

• Median Sternotomy
• Hemisternotomy
• Bilateral Thoracosternotomy

Sternal Closure Systems Regional Outlook (Revenue, USD Million, 2014 - 2025)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Minimally Invasive Surgical Instruments Market Size Is Expected To Reach $42.2 Billion by 2026

The global minimally invasive surgical instruments market size is expected to reach USD 42.2 billion by 2026 progressing at a CAGR of 9.85% over the forecast period according to a new report by Grand View Research, Inc. The preference for minimally invasive surgical (MIS) procedures is rising as they are less traumatic than traditional open surgeries and they facilitate faster recover process. Patients can resume their daily activities in shorter time after minimally invasive procedures.

According to a research article published in the medical journal, JAMA Surgery, in March 2015, the use of minimally invasive surgeries for routine operations of colon, lungs, and appendix can result in reduction of postoperative complications, thereby saving nearly USD 280 million to USD 340 million per year. Investments in minimally invasive surgical instruments are gradually rising in hospitals, thereby driving the market.

In addition, the costs involved in MIS procedures are significantly less than in-patient and conventional open surgeries. Therefore, MIS procedures prove to be beneficial for patients as well as payers. The benefits of minimally invasive surgical instruments in various areas of orthopedics have contributed to the growing demand for less traumatic alternatives with minimum tissue disruption of bones.

Access Research Report of Minimally Invasive Surgical Instruments Market @ https://www.grandviewresearch.com/industry-analysis/minimally-invasive-surgical-instruments-market

Further Key Findings from the Report Suggest:

• Minimal invasive technologies are designed to cause less trauma than traditional open surgeries, reduced blood loss, minimal scarring, and low chances of infection
• Handheld instruments dominated the device segment in terms of revenue share in 2018. On the other hand, electrosurgical devices are expected to witness the fastest growth rate during the forecast period.
• Orthopedic segment dominated the application segment in terms of revenue share in 2018. Minimally invasive surgical procedures in various areas of orthopedics offer alternatives with minimum tissue disruption.
• Continuous adoption of minimally invasive surgical techniques for spine related procedures has led to the expansion of procedural volumes for orthopedic MIS
• Hospital segment held a majority of the end use segment share in 2018. On the other hand, ambulatory surgically centers are likely to experience fastest growth in the coming years.
• Ambulatory surgical centers offer same day surgery and discharge at lower costs. At present, over 5,500 Medicare certified ambulatory care centers are present in the U.S.
• North America held majority of the MIS instruments market share in 2018 due to the presence of supportive reimbursement framework for innovative MIS devices and procedures
• Medtronic, Abbott, NuVasive, Inc., CONMED, Stryker, Smith & Nephew, Zimmer Biomet, and Intuitive Surgical, Inc. are some of the key players operating in this market

Grand View Research has segmented the MIS instruments market based on device, application, end use, and region:

MIS Instruments Device Outlook (Revenue, USD Million, 2015 - 2026)

• Handheld Instruments
• Inflation Devices
• Cutter Instruments
• Guiding Devices
• Electrosurgical Devices
• Auxiliary Devices
• Monitoring & Visualization Devices

MIS Instruments Application Outlook (Revenue, USD Million, 2015 - 2026)

• Cardiac
• Gastrointestinal
• Orthopedic
• Vascular
• Gynecological
• Urological
• Thoracic
• Cosmetic
• Dental
• Others

MIS Instruments End Use Outlook (Revenue, USD Million, 2015 - 2026)

• Hospitals
• Ambulatory Surgical Centers

MIS Instruments Regional Outlook (Revenue, USD Million, 2015 - 2026)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
  • France
  • Italy
  • Spain
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Artificial Tendons & Ligaments Market is Anticipated To Rise at a CAGR of 11.3% from 2019 to 2025

The Report Artificial Tendons and Ligaments Market Analysis Report By Application (Knee Injuries, Shoulder Injuries, Foot & Ankle Injuries), By End Use (Hospitals & Clinics, ASCs), And Segment Forecasts, 2019 - 2025

The global artificial tendons and ligaments market size is anticipated to reach USD 39.7 million by 2025 at an 11.3% CAGR during the forecast period, according to a new report by Grand View Research, Inc. Adoption of artificial grafts is on a rise owing to several benefits over autologous and allogenic grafts, such as high tensile strength, no immune reaction, and abrasion resistance. Increase in number of sports injuries, coupled with rising government efforts to create awareness about sports injuries and available medical reimbursements, is anticipated to fuel market growth.

For instance, the Government of Finland in collaboration with UKK Institute has been conducting a ‘LiVE-program’ since 2016 to improve safety in sports increase awareness about injury risks, sports training, and content of physical activity sessions. Over the past several decades, increase in participation of children and adolescents has been observed in various sports such as football, soccer, bicycles, handball, basketball, and volleyball. Moreover, increase in awareness about physical fitness among people will contribute to market growth.

Other factors likely to contribute to market growth include rising preference for minimally invasive surgery, continuous advancements in surgical procedures, and growing funding and research activities to develop novel materials for synthetic tendons and ligaments. Moreover, positive outcomes reported through various clinical trials pertinent to usage of artificial ligaments will accelerate growth in the near future. For instance, according to a study published in 2017 in NCBI, patients treated with artificial ligament after femoral tumor resection and reconstruction procedures exhibited a more stable hip joint and more active range of movement as compared to patients who did not received a synthetic ligament.

Access Research Report of Artificial Tendons & Ligaments Market @ https://www.grandviewresearch.com/industry-analysis/artificial-tendons-ligaments-market

Further key findings from the report suggest:

• The knee injuries segment held a major share in 2018 owing to increase in incidences of knee injuries, coupled with faster recovery observed with the use of artificial ligaments in comparison to autologous or allogenic grafts
• The hospitals and clinics end-use segment is expected to hold a significant share during the forecast period. Growth of the segment can be attributed to higher readmission rate for treatment of ACL reconstruction procedures and collaborative activities between key players and orthopedic clinics to create awareness about artificial tendons and ligaments.
• As of 2018, Europe accounted for the largest market share. Surge in number of sports injuries among young athletes, rising geriatric population prone to orthopedic disorders, and presence of key players in the region will boost the regional market
• The U.K. artificial tendons and ligaments market is expected to grow substantially over the forecast period. This growth is predicted to be majorly driven by increasing adoption of artificial tendons and ligaments, rising incidence of accidents, R&D of innovative product design, and favorable patient demographics.
• Growing healthcare expenditure, coupled with rising penetration of health insurance in Latin America and Asia Pacific countries such as China, India, Brazil, and Argentina are providing considerable growth opportunities to market players
• Industry players have been involved R&D activities to deliver novel products in the market. Companies are also strategically involved in expanding their geographical presence through distribution agreements to expand their customer base.

Grand View Research has segmented the global artificial tendons and ligaments market on the basis of application, end use, and region:

Artificial Tendons and Ligaments Application Outlook (Revenue, USD Million, 2014 - 2025)

• Knee Injuries
• Shoulder Injuries
• Foot and Ankle Injuries
• Others

Artificial Tendons and Ligaments End-use Outlook (Revenue, USD Million, 2014 - 2025)

• Hospitals and Clinics
• Ambulatory Surgery Centers

Artificial Tendons and Ligaments Regional Outlook (Revenue, USD Million, 2014 - 2025)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Myasthenia Gravis Treatment Market To Make Great Impact In Near Future by 2026

The global myasthenia gravis treatment market size is expected to reach USD 2.06 billion by 2026 at a CAGR of 7.5% through the forecast period, according to a new report by Grand View Research. Increasing awareness of rare diseases, emergence of biologics, and growing adoption of immunotherapies & immunosuppressants are driving the myasthenia gravis (MG) treatment market.

Myasthenia gravis (MG) is a rare autoimmune disorder caused by an antibody mediated neuromuscular transmission obstruction that results in skeletal muscle weakness. Some of the disorders associated with the disease include drooping eyelids, double vision, trouble walking, and trouble talking. Patients with MG present with painless muscle weakness that worsens with repeated use and improves with rest.

According to the National Organization for Rare Disorders (NORD), in the U.S. around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders among general public across the world. Myasthenia gravis occurs more frequently in females than in males, and although symptoms may appear at any age, its onset usually peaks in men in their 50s or 60s and in women during their 20s or 30s.

Medication held the largest market share in the treatment segment and is expected to maintain its market leading position through the forecast period. This is because medications can largely manage the symptoms and dramatically inhibit the immune system. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). However, high cost of treatment and lack of awareness in the developing & underdeveloped countries are expected to inhibit the market growth.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/myasthenia-gravis-mg-treatment-market

Further Key Findings From the Study Suggest:

• Medications are expected to obtain the largest market share in the treatment segment. This can be attributed to the high adoption of immunotherapies and the recent approval of promising drugs.
• Currently, no cure is available for myasthenia gravis, however patients can be treated with medications and surgery for the management of the symptoms.
• North America is likely to dominate the MG treatment market due high healthcare expenditure and favorable reimbursement scenario
• The Asia Pacific region is expected to grow at the highest CAGR over the forecast period due to improving healthcare infrastructure and increasing disposable income in the region.
• Some of the major companies operating in the market include Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc. Novartis AG, Pfizer, Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Bausch Health Companies Inc., and Shire plc.

Grand View Research has segmented the MG treatment market report on the basis of treatment, end use, and region:

Treatment Outlook (Revenue, USD Million, 2015 - 2026)

• Medication
• Surgery
• Others

End Use Outlook (Revenue, USD Million, 2015 - 2026)

• Hospitals
• Clinics
• Others

Regional Outlook (Revenue, USD Million, 2015 - 2026)

• North America 
  • US.
  • Canada
• Europe 
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Russia
• Asia Pacific 
  • Japan
  • China
  • India
  • South Korea
  • Singapore
  • Australia
• Latin America  
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Cancer Supportive Care Drugs Market is Projected to Exhibit a CAGR of 1.0% over the Forecast Period

The global cancer supportive care drugs market size is projected to reach USD 22.9 billion by 2026, as per a new report by Grand View Research, Inc. It is expected to progress at a CAGR of 1.0% over the forecast period. Supportive care in cancer focuses on prevention and management of symptoms and side-effects associated with cancer and its treatment.

Key side effects caused by cancer treatment include anemia, neutropenia, nausea and vomiting, pain, and bone metastasis. Rise in the number of people suffering from the effects of anti-cancer therapies will drive the market, globally. The higher efficacy of supportive care drugs, such as colony stimulating factors (G-CSFs), opioid analgesics, erythropoietins, and antiemetic drugs, among others is anticipated to drive growth of the global cancer supportive care drugs market. High efficiency of these drugs in controlling the adverse effects of cancer and its treatment is projected to drive the demand in near future.

G-CSFs and ESAs therapeutic classes are witnessing a fundamental shift from biologics to biosimilars. The market for cancer pain, chemotherapy induced nausea and vomiting, and cancer induced bone diseases will grow significantly during the forecast period, due to new product launches and high unmet needs. The cancer pain market is estimated to witness a shift from opioids to non-opioids therapies. The shift will be backed by patent loss, high mortality, addiction, and major safety issues associated with narcotic agents.

Access Research Report of Cancer Supportive Care Drugs Market @
https://www.grandviewresearch.com/industry-analysis/cancer-supportive-care-drugs-market

Further key findings from the report suggest:

• Some of the key market players are Amgen, Merck, Novartis, Johnson & Johnson, Roche, Helsinn Healthcare, Heron Pharma, Tesaro, and Purdue Pharma. Amgen led the global cancer supportive care market in 2018, capturing over 30% market share
• By therapeutic class, the global ESAs market for CIA was valued at USD 1,838 million in 2018 and is expected to decline with a CAGR of 6.0% over the forecast period. The biologics segment is anticipated to lose its market share due to patent expiration of major brands such as Epogen
• North America led the cancer supportive care drugs market in 2018 and is expected to maintain its position during the forecast period
• Asia Pacific is expected to witness lucrative growth over the forecast period, owing to improvements in healthcare infrastructure and increasing government initiatives
• Late stage pipeline products include non-opioids such as Tanezumab and HTX-011. Newer immunotherapies directed against PD-1 ligands and PD-L1 proteins have shown to be more effective with a superior safety profile

Grand View Research has segmented the global cancer supportive care drugs market based on therapeutic class and region:

Cancer Supportive Care Drugs Therapeutic Class Outlook (Revenue, USD Million, 2015 - 2026)

• G-CSFs (Granulocyte-colony Stimulating Factors)
• ESAs (Erythropoiesis Stimulating Agents)
• Anti-emetics
• Bisphosphonates
• Opioids
• NSAIDs

Cancer Supportive Care Drugs Regional Outlook (Revenue, USD Million, 2015 - 2026)

• North America
  • US.
  • Canada
• Europe
  • UK.
  • Germany
  • Italy
  • France
  • Spain
• Asia Pacific
  • India
  • China
  • Japan
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.